PPARs in inflammation, atherosclerosis and thrombosis

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 4, 2001, Pages 187-194

  Duez, Hélène ^a   Fruchart, Jean Charles ^a   Staels, Bart ^a  

^a UNIV LILLE   (France)

Author keywords

Atherosclerosis; Gene Expression; Inflammatory Response; PPARs; Thrombosis

Indexed keywords

FATTY ACID DERIVATIVE; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DIFFERENTIATION; CHOLESTEROL TRANSPORT; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE ADHERENCE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW; THROMBOGENICITY; THROMBOSIS;

ARTERIOSCLEROSIS; IMMUNOCOMPETENCE; INFLAMMATION; LIGANDS; LIPID METABOLISM; MACROPHAGES; MONOCYTES; MUSCLE, SMOOTH; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THROMBOSIS; TRANSCRIPTION FACTORS;

EID: 0034875893     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800402     Document Type: Article

References (74)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650.
2. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147–1156.
3. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573–25580.
4. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614–7619.
5. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17–23.
6. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000; 164: 1364–1371. This study, together with Padilla et al. [8], Yang et al. [9], and Faveeuw et al. [16] suggests that PPARs may be important in the control of the immune response by acting on lymphocytes.
7. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4: 281–299.
8. Padilla J, Kaur K, Harris SG, Phipps RP. PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Ann N Y Acad Sci 2000; 905: 97–109.
9. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541–4544.
10. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394–402.
11. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125–3131.
12. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 546–551.
13. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246: 370–374.
14. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790–793.
15. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097–1103.
16. Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P, et al Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 2000; 486: 261–266.
17. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, et al CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101: 2411–2417.
18. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048–32054.
19. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79–82.
20. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, et al Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 2000; 275: 32681–32687.
21. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of Ikappa B alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275: 36703–36707.
22. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39–43.
23. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94: 4312–4317.
24. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318–4323.
25. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 2000; 471: 34–38.
26. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229–240.
27. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et al Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378–382.
28. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1997; 1: 235–241.
29. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406–3410.
30. Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T. Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. FEBS Lett 2000; 467: 259–262.
31. Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000; 20: 191–199.
32. Gosset P, Charbonnier A-S, Delerive P, Fontaine J, Staels B, Pestel J, et al PPARƔ activators affect the maturation of human dendritic cells. 2001 Eur J Immunol. In press.
33. Tanaka T, Itoh H, Doi K, Fukunaga Y, Hosoda K, Shintani M, et al Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 1999; 42: 702–710.
34. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833–32841.
35. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, et al15-deoxy-delta(12, 14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000; 106: 189–197.
36. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354–1361.
37. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, et al Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998; 36: 345–349.
38. Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, et al Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 1999; 93: 2991–2998.
39. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96: 2137–2143.
40. Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, et al Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32: 1648–1656.
41. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849–853.
42. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818–1820.
43. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233–241.
44. Pineda TI, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 1999; 10: 151–159.
45. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527–550.
46. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999; 20: 649–688.
47. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000; 38: 3–11.
48. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241–252.
49. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48–52.
50. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, et al The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7: 41–47.
51. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–86.
52. Callejas NA, Castrillo A, Bosca L, Martin-Sanz P. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators. J Pharmacol Exp Ther 1999; 288: 1235–1241.
53. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, et al Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403: 103–108.
54. Colville-Nash PR, Qureshi SS, Willis D, Willoughby DA. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1. J Immunol 1998; 161: 978–984.
55. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53–58.
56. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523–531.
57. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, et al Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049–1056.
58. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, et al Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest 2000; 106: 793–802.
59. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235–238.
60. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, et al Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000; 267: 345–349.
61. Neve B, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, et al PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001; 103: 207–212.
62. Marx N, Mackman N, Schönbeck U, Yilmaz N, Hombach V, Libby P, et al PPARα activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001; 103: 213–219.
63. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311–1318.
64. Ikeda U, Shimpo M, Murakami Y, Shimada K. Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension 2000; 35: 1232–1236.
65. Murao K, Imachi H, Momoi A, Sayo Y, Hosokawa H, Sato M, et al Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999; 454: 27–30.
66. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, et al Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094–2104.
67. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164: 6503–6508.
68. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9.
69. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, et al Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 1999; 258: 431–435.
70. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, et al Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 181–186.
71. Kockx M, Princen HM, Kooistra T. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes — role of the peroxisome proliferator-activated receptor-alpha. Thromb Haemost 1998; 80: 942–948.
72. Nilsson L, Takemura T, Eriksson P, Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1577–1581.
73. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, et al Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138: 217–225.
74. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418.